Browsing Tag
Vir Biotechnology
5 posts
From healthtech to AI: What Kartika Saran’s CFO move reveals about SPARC’s ambitions
SPARC AI names Kartika Saran as CFO in a move signaling strategic capital readiness. Read why this hire may reshape its investor strategy and scaling plan.
Can Norgine turn Vir Biotechnology’s hepatitis D duo into a regional blockbuster? €550m deal signals big bet
Vir Biotechnology licenses its hepatitis D therapy to Norgine in a €550M deal. Find out what this means for commercialization, access, and biotech strategy.
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.
Vir Biotechnology just finished its HDV Phase 3 enrolment early—here’s why investors are watching
Vir Biotechnology completes ECLIPSE 1 trial enrolment early and secures a funding runway into mid-2027. See what this means for its hepatitis delta ambitions.
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.